COVID-19 and Immune-Engaging Cancer Treatment | Oncology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment

Educational Objective
To understand the COVID-19 infection risk for patients undergoing immune-engaging cancer treatment
1 Credit CME

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently intensifying across the world. The US alone accounts for nearly one-third of the global disease burden and approximately one-fifth of deaths. The number of reported cases has been doubling weekly in the US, emphasizing the contagiousness of the disease among the US population due to a lack of immunity to the novel virus.1

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Muhammad Bilal Abid, MD, MRCP, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 (mabid@mcw.edu).

Published Online: May 20, 2020. doi:10.1001/jamaoncol.2020.2367

Conflict of Interest Disclosures: None reported.

References
1.
WHO Coronavirus disease 2019 (COVID-19) situation report 86. March 16, 2020. Accessed April 15, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_6
2.
Huang  C , Wang  Y , Li  X ,  et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.   Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5PubMedGoogle ScholarCrossref
3.
Liang  W , Guan  W , Chen  R ,  et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.   Lancet Oncol. 2020;21(3):335-337. doi:10.1016/S1470-2045(20)30096-6PubMedGoogle ScholarCrossref
4.
Porcheddu  R , Serra  C , Kelvin  D , Kelvin  N , Rubino  S .  Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.   J Infect Dev Ctries. 2020;14(2):125-128. doi:10.3855/jidc.12600PubMedGoogle ScholarCrossref
5.
Ruan  Q , Yang  K , Wang  W , Jiang  L , Song  J .  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.   Intensive Care Med. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-xPubMedGoogle Scholar
6.
Nishino  M , Giobbie-Hurder  A , Hatabu  H , Ramaiya  NH , Hodi  FS .  Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis.   JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.2453PubMedGoogle ScholarCrossref
7.
Lee  DW , Gardner  R , Porter  DL ,  et al.  Current concepts in the diagnosis and management of cytokine release syndrome.   Blood. 2014;124(2):188-195. doi:10.1182/blood-2014-05-552729PubMedGoogle ScholarCrossref
8.
Favipiravir combined with tocilizumab in the treatment of corona virus disease. 2019. ClinicalTrials.gov identifier: NCT04310228. Updated April 10, 2020. Accessed May 11, 2020. https://clinicaltrials.gov/ct2/show/NCT04310228
9.
A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry identifier: ChiCTR2000029765. Accessed May 11, 2020. http://www.chictr.org.cn/showprojen.aspx?proj=49409
10.
Russell  CD , Millar  JE , Baillie  JK .  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.   Lancet. 2020;395(10223):473-475. doi:10.1016/S0140-6736(20)30317-2PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close